Changes in Treatment Patterns and Globe Salvage Rate of Advanced Retinoblastoma in Korea: Efficacy of Intra-Arterial Chemotherapy
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Demographics and Treatment Information
3.2. Distribution of Patients and the Reason for Enucleation
3.3. Overall 5-Year Globe Salvage, Recurrence-Free, and Metastasis-Free Rates
3.4. Complications Associated with IVC and IAC Treatments
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Shields, C.L.; Shields, J.A.; Baez, K.; Cater, J.R.; De Potter, P. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer 1994, 73, 692–698. [Google Scholar] [CrossRef]
- Shields, C.L.; Shields, J.A.; Baez, K.A.; Cater, J.; De Potter, P.V. Choroidal invasion of retinoblastoma: Metastatic potential and clinical risk factors. Br. J. Ophthalmol. 1993, 77, 544–548. [Google Scholar] [CrossRef] [Green Version]
- Wilson, M.W.; Qaddoumi, I.; Billups, C.; Haik, B.G.; Rodriguez-Galindo, C. A clinicopathological correlation of 67 eyes primarily enucleated for advanced intraocular retinoblastoma. Br. J. Ophthalmol. 2011, 95, 553–558. [Google Scholar] [CrossRef] [PubMed]
- Kaliki, S.; Shields, C.L.; Rojanaporn, D.; Al-Dahmash, S.; McLaughlin, J.P.; Shields, J.A.; Eagle, R.C., Jr. High-risk retinoblastoma based on international classification of retinoblastoma: Analysis of 519 enucleated eyes. Ophthalmology 2013, 120, 997–1003. [Google Scholar] [CrossRef]
- Wilson, M.W.; Haik, B.G.; Liu, T.; Merchant, T.E.; Rodriguez-Galindo, C. Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma. Am. J. Ophthalmol. 2005, 140, 397–406. [Google Scholar] [CrossRef] [PubMed]
- Villegas, V.M.; Hess, D.J.; Wildner, A.; Gold, A.S.; Murray, T.G. Retinoblastoma. Curr. Opin. Ophthalmol. 2013, 24, 581–588. [Google Scholar] [CrossRef]
- Shields, C.L.; Fulco, E.M.; Arias, J.D.; Alarcon, C.; Pellegrini, M.; Rishi, P.; Kaliki, S.; Bianciotto, C.G.; Shields, J.A. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye 2013, 27, 253–264. [Google Scholar] [CrossRef] [Green Version]
- Shields, C.L.; Mashayekhi, A.; Au, A.K.; Czyz, C.; Leahey, A.; Meadows, A.T.; Shields, J.A. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology 2006, 113, 2276–2280. [Google Scholar] [CrossRef]
- Shields, C.L.; Ramasubramanian, A.; Thangappan, A.; Hartzell, K.; Leahey, A.; Meadows, A.T.; Shields, J.A. Chemoreduction for group e retinoblastoma: Comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Ophthalmology 2009, 116, 544–551.e541. [Google Scholar] [CrossRef]
- Shields, C.L.; Kaliki, S.; Al-Dahmash, S.; Rojanaporn, D.; Leahey, A.; Griffin, G.; Jabbour, P.; Shields, J.A. Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation. Retina 2013, 33, 2103–2109. [Google Scholar] [CrossRef]
- Pekacka, A. The role of intraarterial chemotherapy in the management of retinoblastoma. J. Ophthalmol. 2020, 2020, 3638410. [Google Scholar] [CrossRef] [Green Version]
- Suzuki, S.; Yamane, T.; Mohri, M.; Kaneko, A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: The long-term prognosis. Ophthalmology 2011, 118, 2081–2087. [Google Scholar] [CrossRef] [PubMed]
- Chan, H.S.; DeBoer, G.; Thiessen, J.J.; Budning, A.; Kingston, J.E.; O′Brien, J.M.; Koren, G.; Giesbrecht, E.; Haddad, G.; Verjee, Z. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 1996, 2, 1499–1508. [Google Scholar]
- Hahn, S.M.; Kim, H.S.; Kim, D.J.; Lee, S.C.; Lyu, C.J.; Han, J.W. Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma. Pediatr. Hematol. Oncol. 2016, 33, 74–82. [Google Scholar] [CrossRef]
- Abramson, D.H.; Schefler, A.C. Update on retinoblastoma. Retina 2004, 24, 828–848. [Google Scholar] [CrossRef] [PubMed]
- Ancona-Lezama, D.; Dalvin, L.A.; Shields, C.L. Modern treatment of retinoblastoma: A 2020 review. Indian J. Ophthalmol. 2020, 68, 2356–2365. [Google Scholar] [PubMed]
- Ravindran, K.; Dalvin, L.A.; Pulido, J.S.; Brinjikji, W. Intra-arterial chemotherapy for retinoblastoma: An updated systematic review and meta-analysis. J. Neurointerv. Surg. 2019, 11, 1266–1272. [Google Scholar] [CrossRef]
- Munier, F.L.; Mosimann, P.; Puccinelli, F.; Gaillard, M.C.; Stathopoulos, C.; Houghton, S.; Bergin, C.; Beck-Popovic, M. First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group d retinoblastoma: Evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment. Br. J. Ophthalmol. 2017, 101, 1086–1093. [Google Scholar]
- Chen, M.; Zhao, J.; Xia, J.; Liu, Z.; Jiang, H.; Shen, G.; Li, H.; Jiang, Y.; Zhang, J. Intra-arterial chemotherapy as primary therapy for retinoblastoma in infants less than 3 months of age: A series of 10 case-studies. PLoS ONE 2016, 11, e0160873. [Google Scholar] [CrossRef] [Green Version]
- Gobin, Y.P.; Dunkel, I.J.; Marr, B.P.; Brodie, S.E.; Abramson, D.H. Intra-arterial chemotherapy for the management of retinoblastoma: Four-year experience. Arch. Ophthalmol. 2011, 129, 732–737. [Google Scholar] [CrossRef] [Green Version]
- Chen, Q.; Zhang, B.; Dong, Y.; Mo, X.; Zhang, L.; Xia, J.; Zhang, J.; Zhang, S. Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma. Cancer Chemother. Pharmacol. 2020, 85, 723–730. [Google Scholar] [CrossRef]
- Xu, K.; Liu, J.; Zhang, C. Intra-arterial chemotherapy combined with vec intravenous chemotherapy in the treatment of advanced retinoblastoma. J. BU ON. Off. J. Balk. Union Oncol. 2020, 25, 1199–1205. [Google Scholar]
- Kiratli, H.; Koç, İ.; Varan, A.; Akyüz, C. Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma. Eur. J. Ophthalmol. 2017, 27, 423–427. [Google Scholar] [CrossRef]
- Abramson, D.H.; Ji, X.; Francis, J.H.; Catalanotti, F.; Brodie, S.E.; Habib, L. Intravitreal chemotherapy in retinoblastoma: Expanded use beyond intravitreal seeds. Br. J. Ophthalmol. 2019, 103, 488–493. [Google Scholar] [CrossRef] [PubMed]
- Dalvin, L.A.; Kumari, M.; Essuman, V.A.; Shohelly Shipa, S.; Ancona-Lezama, D.; Lucio-Alvarez, J.A.; Jabbour, P.; Shields, C.L. Primary intra-arterial chemotherapy for retinoblastoma in the intravitreal chemotherapy era: Five years of experience. Ocul. Oncol. Pathol. 2019, 5, 139–146. [Google Scholar] [CrossRef] [PubMed]
1985–2009 (Eyes = 33) | 2010–2020 (Eyes = 64) | Total | p-Value 1 | |
---|---|---|---|---|
Bilateral tumors (Any grade) 2 | 9 (29.0%) | 19 (31.7%) | 28 (30.8%) | 0.817 |
Bilateral tumors (Group D/E) 2 | 2 (6.5%) | 4 (6.7%) | 6 (6.6%) | 0.999 |
ICRB group | 0.670 | |||
Group D | 15 (45.5%) | 26 (40.6%) | 41 (42.3%) | |
Group E | 18 (54.5%) | 38 (59.4%) | 56 (57.7%) | |
Total number of IAC | - | 202 | 202 | - |
Melphalan | - | 116 (57.4%) | 116 (57.4%) | - |
Melphalan + Topotecan | - | 80 (39.6%) | 80 (39.6%) | - |
Topotecan | - | 1 (0.5%) | 1 (0.5%) | - |
Topotecan + Carboplatin | - | 5 (2.5%) | 5 (2.5%) | - |
Total number of IVitC | - | 193 | 193 | - |
Melphalan | - | 109 (56.5%) | 109 (56.5%) | - |
Topotecan | - | 74 (38.3%) | 74 (38.3%) | - |
Methotrexate | - | 10 (5.2%) | 10 (5.2%) | - |
Additional treatment | ||||
TTT | 5 (15.2%) | 33 (51.6%) | 38 (39.2%) | 0.001 |
Laser photocoagulation | 3 (9.1%) | 16 (25.0%) | 19 (19.6%) | 0.103 |
External cryotherapy | 3 (9.1%) | 14 (21.9%) | 17 (17.5%) | 0.161 |
Cataract surgery | 1 (3.0%) | 4 (6.3%) | 5 (5.2%) | 0.659 |
Vitrectomy | 0 (0.0%) | 3 (4.7%) | 3 (3.1%) | 0.549 |
EBRT | 7 (21.2%) | 2 (3.1%) | 9 (9.3%) | 0.006 |
Brachytherapy | 0 (0.0%) | 1 (1.6%) | 1 (1.0%) | 0.999 |
Treatment outcomes | ||||
Enucleation | 32 (97.0%) | 33 (51.6%) | 65 (67.0%) | <0.001 |
Recurrence | 6 (18.2%) | 28 (43.8%) | 34 (35.1%) | 0.039 |
Metastasis | 1 (3.0%) | 0 (0.0%) | 1 (1.0%) | 0.340 |
1985–2009 | 2010–2020 | |||
---|---|---|---|---|
Group D N = 15 | Group E N = 18 | Group D N = 26 | Group E N = 38 | |
Primary enucleation | 7 (46.7%) | 12 (66.7%) | 2 (7.7%) | 7 (18.4%) |
IVC | 8 (53.3%) | 6 (33.3%) | 1 (3.8%) | 4 (10.5%) |
IVC + IAC | 0 (0%) | 0 (0%) | 23 (88.5%) | 27 (71.1%) |
Secondary enucleation | 7 (87.5%) | 6 (100.0%) | 10 (41.7%) | 14 (45.2%) |
Clinically evident tumor | 6 (85.7%) | 2 (33.3%) | 5 (50.0%) | 9 (64.3%) |
Total RD with suspicious recurrence | 1 (14.3%) | 2 (33.3%) | 1 (10.0%) | 2 (14.3%) |
Painful eye with phthisis bulbi | 0 (0.0%) | 2 (33.3%) | 4 (40.0%) | 3 (21.4%) |
Adverse Events | Number (%) |
---|---|
Systemic chemotherapy-related | |
Fever | 4 (8.3%) |
Hypotension | 1 (2.1%) |
Seizure | 1 (2.1%) |
Intraarterial chemotherapy-related | |
Eyelid swelling | 11 (22.9%) |
Erythema | 7 (14.6%) |
Conjunctival injection | 6 (12.5%) |
Ptosis | 2 (4.2%) |
Strabismus | 2 (4.2%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, D.H.; Han, J.W.; Hahn, S.M.; Kim, B.M.; Lyu, C.J.; Lee, S.C.; Kim, D.J.; Lee, C.S. Changes in Treatment Patterns and Globe Salvage Rate of Advanced Retinoblastoma in Korea: Efficacy of Intra-Arterial Chemotherapy. J. Clin. Med. 2021, 10, 5421. https://doi.org/10.3390/jcm10225421
Lee DH, Han JW, Hahn SM, Kim BM, Lyu CJ, Lee SC, Kim DJ, Lee CS. Changes in Treatment Patterns and Globe Salvage Rate of Advanced Retinoblastoma in Korea: Efficacy of Intra-Arterial Chemotherapy. Journal of Clinical Medicine. 2021; 10(22):5421. https://doi.org/10.3390/jcm10225421
Chicago/Turabian StyleLee, Dong Hyun, Jung Woo Han, Seung Min Hahn, Byung Moon Kim, Chuhl Joo Lyu, Sung Chul Lee, Dong Joon Kim, and Christopher Seungkyu Lee. 2021. "Changes in Treatment Patterns and Globe Salvage Rate of Advanced Retinoblastoma in Korea: Efficacy of Intra-Arterial Chemotherapy" Journal of Clinical Medicine 10, no. 22: 5421. https://doi.org/10.3390/jcm10225421